Utah Medical Products
Utah Medical Products
UTMD
NASDAQ
57.30
USD
0.00%
About
Utah Medical Products, Inc. is engaged in the business of producing medical services. The Company markets a range of medical devices used in critical care areas, especially the neonatal intensive care unit (NICU), the labor and delivery (L&D) department and the women's health center in hospitals, as well as medical devices sold to outpatient clinics and physician's offices.
Its products include BT-CATH, CVX-RIPE, AROM-COT, MUC-X, CORDGUARD, DISPOSA-HOOD, DELTRAN PLUS, GESCO, PICC-NATE, LETZ System, Filshie Clip System, PATHFINDER PLUS, SUPRAPUBIC CATHETERIZATION, LIBERTY System, ENDOCURETTE, LUMIN, and BioPharm HP-PRT, among others. BT-CATH is a uterine balloon tamponade catheter for controlling severe postpartum hemorrhage.
MUC-X is an aspiration device used immediately after birth to clear neonatal respiratory passages and reduce exposure to potential infections. AROM-CO is a finger cover with a prong designed to rupture maternal membranes with less patient pain and anxiety..
Financials Amount (in millions)
Income statement
Balance sheet
Cash flow
Ratios
| Price and Volume | |
|---|---|
| Volume | |
| Ten Day Average Volume | 7.6K |
| Three Month Average Volume | 366.0K |
| High Low | |
| Fifty-Two Week High | 92.51 USD |
| Fifty-Two Week Low | 65.62 USD |
| Fifty-Two Week High Date | 01 Sep 2023 |
| Fifty-Two Week Low Date | 05 Jul 2024 |
| Price and Volume | |
| Current Price | 67.99 USD |
| Beta | 0 |
| Relative Price Change | |
| Four Week Relative Price Change | -4.60% |
| Thirteen Week Relative Price Change | -6.98% |
| Twenty-Six Week Relative Price Change | -11.25% |
| Fifty-Two Week Relative Price Change | -40.77% |
| Year-to-Date Relative Price Change | -31.83% |
| Price Change | |
| One Day Price Change | 0.10% |
| Thirteen Week Price Change | -0.44% |
| Twenty-Six Week Price Change | -2.41% |
| Five Day Price Change | -0.85% |
| Fifty-Two Week Price Change | -25.78% |
| Year-to-Date Price Change | -19.27% |
| Month-to-Date Price Change | -2.31% |
| Per Share Data | |
|---|---|
| Book Value | |
| Book Value Per Share (Last Fiscal Year) | 35.34793 USD |
| Book Value Per Share (Most Recent Quarter) | 35.45356 USD |
| Tangible Book Value Per Share (Last Fiscal Year) | 30.2135 USD |
| Tangible Book Value Per Share (Most Recent Quarter) | 30.44756 USD |
| EBITD | |
| EBITD Per Share (Trailing Twelve Months) | 5.37558 USD |
| Revenue | |
| Revenue Per Share (Last Fiscal Year) | 13.80918 USD |
| Revenue Per Share (Trailing Twelve Months) | 12.9177 USD |
| Dividend | |
| Dividend Per Share (Last Fiscal Year) | 1.19 USD |
| Dividend Per Share (Trailing Twelve Months) | 1.2 USD |
| Dividend Per Share (5 Year) | 1.147 USD |
| Earnings Per Share | |
| Excluding Extraordinary Items (Last Fiscal Year) | 4.57382 USD |
| Excluding Extraordinary Items (Trailing Twelve Months) | 4.33181 USD |
| Normalized (Last Fiscal Year) | 4.95177 USD |
| Basic Excluding Extraordinary Items (Last Fiscal Year) | 4.58391 USD |
| Basic Excluding Extraordinary Items (Trailing Twelve Months) | 4.33641 USD |
| Including Extraordinary Items (Last Fiscal Year) | 4.57382 USD |
| Including Extraordinary Items (Trailing Twelve Months) | 4.33181 USD |
| Cash | |
| Cash Per Share (Last Fiscal Year) | 25.58347 USD |
| Cash Per Share (Most Recent Quarter) | 25.49843 USD |
| Cash Flow Per Share (Last Fiscal Year) | 6.31015 USD |
| Cash Flow Per Share (Trailing Twelve Months) | 5.48541 USD |
| Free Cash Flow Per Share (Trailing Twelve Months) | 3.81779 USD |
| Margins | |
|---|---|
| Cash Flow Revenue | |
| Cash Flow Revenue (5 Year) | 21 |
| Cash Flow Revenue (Trailing Twelve Months) | 30 |
| Pretax Margin | |
| Pretax Margin (Trailing Twelve Months) | 40.38% |
| Pretax Margin (Last Fiscal Year) | 40.00% |
| Pretax Margin (5 Year) | 38.04% |
| Gross Margin | |
| Gross Margin (Last Fiscal Year) | 59.81% |
| Gross Margin (Trailing Twelve Months) | 58.99% |
| Gross Margin (5 Year) | 61.57% |
| Operating Margin | |
| Operating Margin (Last Fiscal Year) | 33.40% |
| Operating Margin (Trailing Twelve Months) | 32.71% |
| Operating Margin (5 Year) | 36.06% |
| Net Profit Margin | |
| Net Profit Margin (Last Fiscal Year) | 33.12% |
| Net Profit Margin (Trailing Twelve Months) | 33.56% |
| Net Profit Margin (5 Year) | 30.51% |
| Growth | |
|---|---|
| Book Value | |
| Book Value Per Share (5 Year) | 8.12% |
| Tangible Book Value (5 Year) | 12.64% |
| Free Operating Cash Flow | |
| Free Operating Cash Flow (5 Year) | 6.95% |
| Revenue | |
| Revenue Change MRQ vs 1 Year Ago | -19.17% |
| Revenue Growth (3 Year) | 3.64% |
| Revenue Change (Trailing Twelve Months) | -10.28% |
| Revenue Per Share Growth | 4.27% |
| Revenue Growth (5 Year) | 5.99% |
| Capital Spending Debt | |
| Capital Spending (5 Year) | 9.71% |
| Total Debt (5 Year) | -99,999.99% |
| Dividends | |
| Dividend Growth (3 Year) | 1.89% |
| Earnings Per Share | |
| EPS Change MRQ vs 1 Year Ago | -15.30% |
| EPS Change (Trailing Twelve Months) | -8.76% |
| EPS Growth (3 Year) | 2.27% |
| EPS Growth (5 Year) | 14.94% |
| EBITDA | |
| EBITDA (5 Year) | 2.71% |
| EBITDA (5 Year Interim) | -2.45% |
| Net Profit Margin | |
| Net Profit Margin Growth (5 Year) | -1.92% |
| Valuation | |
|---|---|
| Total Price to Book | |
| Price to Tangible Book (Last Fiscal Year) | 2 |
| Price to Tangible Book (Most Recent Quarter) | 2 |
| Price to Free Cash Flow | |
| Price to Free Cash Per Share (Last Fiscal Year) | 14 |
| Price to Free Cash Per Share (Trailing Twelve Months) | 17 |
| Net Debt | |
| Net Debt (Most Recent Quarter) | -89,219,000 |
| Net Debt (Last Fiscal Year) | -92,868,000 |
| Price to Sales | |
| Price to Sales (Last Fiscal Year) | 5 |
| Price to Sales (Trailing Twelve Months) | 5 |
| Price to Earnings | |
| PE Excluding Extraordinary Items (Last Fiscal Year) | 16 |
| PE Normalized (Last Fiscal Year) | 14 |
| PE Basic Excluding Extraordinary Items (Trailing Twelve Months) | 15 |
| PE Excluding Extraordinary Items High (Trailing Twelve Months) | 33 |
| PE Excluding Extraordinary Items Low (Trailing Twelve Months) | 15 |
| PE Including Extraordinary Items (Trailing Twelve Months) | 16 |
| Dividends | |
| Dividend Yield (5 Year) | 1.21% |
| Dividend Yield | 1.76% |
| Current Dividend Yield | 1.76% |
| Price to Book | |
| Price to Book (Last Fiscal Year) | 2 |
| Price to Book (Most Recent Quarter) | 2 |
| Financial Strength | |
|---|---|
| Debt to Equity | |
| Long Term Debt to Equity (Last Fiscal Year) | 0 |
| Long Term Debt to Equity (Most Recent Quarter) | 0 |
| Payout Ratio | |
| Payout Ratio (Last Fiscal Year) | 25.85% |
| Payout Ratio (Trailing Twelve Months) | 27.46% |
| Quick Ratio | |
| Quick Ratio (Last Fiscal Year) | 21 |
| Quick Ratio (Most Recent Quarter) | 24 |
| Enterprise Value | |
| Current Enterprise Value to Free Cash Flow (Last Fiscal Year) | 8 |
| Current Enterprise Value to Free Cash Flow (Trailing Twelve Months) | 10 |
| Current Ratio | |
| Current Ratio (Last Fiscal Year) | 23 |
| Current Ratio (Most Recent Quarter) | 26 |
| Free Cash Flow | |
| Free Cash Flow (Last Fiscal Year) | 17.4M |
| Free Cash Flow (Trailing Twelve Months) | 13.8M |
| Net Interest Coverage | |
| Net Interest Coverage (Last Fiscal Year) | -100,000 |
| Net Interest Coverage (Trailing Twelve Months) | -100,000 |
| Total Debt to Equity | |
| Total Debt to Equity (Last Fiscal Year) | 0 |
| Total Debt to Equity (Most Recent Quarter) | 0 |
| Management Effectiveness | |
|---|---|
| Return on Assets | |
| Return on Assets (Last Fiscal Year) | 12.83% |
| Return on Assets (Trailing Twelve Months) | 12.00% |
| Return on Assets (5 Year) | 12.69% |
| Return on Equity | |
| Return on Equity (Last Fiscal Year) | 13.72% |
| Return on Equity (Trailing Twelve Months) | 12.72% |
| Return on Equity (5 Year) | 13.75% |
| Return on Investment | |
| Return on Investment (Last Fiscal Year) | 13.38% |
| Return on Investment (Trailing Twelve Months) | 12.43% |
| Return on Investment (5 Year) | 13.19% |